Clinical Research Papers:
Apatinib-based targeted therapy against pulmonary sarcomatoid carcinoma: a case report and literature review
Metrics: PDF 1352 views | HTML 4815 views | ?
Abstract
Xiaofeng Li1, Yueming He2, Jinfeng Zhu1, Hongxia Pang1, Yongwei Lin1 and Jinyang Zheng3
1Department of Oncology, Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou 362000, China
2Department of Respiratory Diseases, Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou 362000, China
3Department of Pathology, Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou 362000, China
Correspondence to:
Jinyang Zheng, email: [email protected]
Keywords: angiogenesis; apatinib; sarcomatoid carcinoma; targeted therapy
Received: September 29, 2017 Accepted: March 17, 2018 Published: September 14, 2018
ABSTRACT
Sarcomatoid carcinoma is a rare malignancy characterized by a combination of epithelial and sarcoma or sarcoma-like components. In this study, we reported one case of pulmonary sarcomatoid carcinoma and evaluated the safety and efficacy of apatinib, a tyrosine kinase inhibitor selectively targeting vascular endothelial growth factor receptor 2, in treating this disease. The tumor mass was detected in the left lung of a 75-year-old man and showed positive immunostaining for cytokeratin (CK) 7, CK8, smooth muscle actin, CD31, and CD34. Next-generation sequencing analysis identified 4 mutations in NF1 (p.Q347Sfs*29), CDKN2A (p.G23V), ERBB3 (p.V104L), and TP53 (p.V157F) genes. The patient was given apatinib (250 mg) orally once per day. Sustained tumor regression was observed after apatinib treatment. There was no sever complication associated with apatinib therapy. In conclusion, apatinib-based targeted therapy may represent an important option for patients with sarcomatoid carcinoma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25989